X4 Pharmaceuticals, Inc (XFOR) - Dilution Analysis

S-3 filing: This is an S-3 filing for X4 Pharmaceuticals, Inc. registering for sale common stock with an aggregate offering price of up to $75,000,000 through Jefferies LLC as sales agent.

10-Q filing | 94.3M shares outstanding

8-K filing: X4 Pharmaceuticals closed two private placements on August 13, 2025, raising $85 million through the sale of common stock and pre-funded warrants, with approximately 87.2 million fully diluted shares outstanding following the closing. ($25.0M proceeds)

8-K filing: X4 Pharmaceuticals, Inc. entered into a securities purchase agreement with institutional accredited investors to issue and sell 11,040,776 shares of common stock at $1.42 per share and pre-funded warrants to purchase 31,234,731 shares of common stock at $1.419 per share, with expected gross proceeds of approximately $60 million.

8-K filing: X4 Pharmaceuticals, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing the Company to sell up to $40,000,000 of its common stock to Lincoln Park, with the Company issuing 137,099 shares of Common Stock to Lincoln Park as a commitment fee.

10-Q filing | 5.8M shares outstanding

8-K filing: Stock split 1-for-30 | Outstanding: 173,662,376 → 5,788,166

10-K filing | 173.7M shares outstanding

10-Q filing | 170.5M shares outstanding

10-Q filing | 168.5M shares outstanding

10-Q filing | 167.9M shares outstanding

10-K filing | 177.8M shares outstanding

10-Q filing | 167.3M shares outstanding

S-3 filing: The company may offer shares of its common stock, shares of its preferred stock, various series of debt securities and warrants to purchase any of such securities, up to a total aggregate offering price of $300,000,000 from time to time in one or more offerings under this prospectus.

10-Q filing | 168.7M shares outstanding

S-3 filing: S-3 filing for common stock offering by selling stockholders.

8-K filing: X4 Pharmaceuticals, Inc. entered into a securities purchase agreement to issue and sell shares of common stock and pre-funded warrants in a private placement, expected to close around May 18, 2023, with gross proceeds of approximately $65 million. ($65.0M proceeds)

10-Q filing | 122.2M shares outstanding

10-K filing | 122.2M shares outstanding

8-K filing: X4 Pharmaceuticals, Inc. entered into an underwriting agreement for the issuance and sale of 52,300,000 shares of common stock, pre-funded warrants to purchase 6,800,000 shares of common stock, and Class C warrants to purchase 29,550,000 shares of common stock or pre-funded warrants at a price of $1.10 per share for common stock and $1.099 per pre-funded warrant, with an expected closing on or about December 9, 2022. ($65.0M proceeds)

10-Q filing | 69.2M shares outstanding

10-Q filing | 68.6M shares outstanding

S-3 filing: This S-3 filing relates to the resale from time to time of up to 101,850,730 shares of common stock of X4 Pharmaceuticals, Inc. by the selling stockholders.

8-K filing: X4 Pharmaceuticals, Inc. entered into a securities purchase agreement with institutional investors to issue and sell shares of common stock, pre-funded warrants, and warrants in a private placement, expecting gross proceeds of approximately $55 million. ($55.0M proceeds)

10-Q filing | 30.8M shares outstanding

S-3 filing: This prospectus covers the sale or other disposition by the Selling Stockholder of up to the total number of shares of our Common Stock that were issued to the Selling Stockholder pursuant to the Purchase Agreement, plus the total number of shares of our Common Stock issuable upon exercise of the pre-funded warrants issued to the Selling Stockholder pursuant to the Purchase Agreement, without giving effect to the Beneficial Ownership Limitation.

10-K filing | 30.8M shares outstanding

8-K filing: X4 Pharmaceuticals, Inc. entered into a securities purchase agreement to issue and sell 900,000 shares of common stock at $1.80 per share and pre-funded warrants to purchase 766,666 shares of common stock at a price of $0.01 per share, with expected gross proceeds of approximately $3.0 million.

8-K filing: X4 Pharmaceuticals, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, where the Company can sell shares of its common stock up to $50,000,000, and as an initial purchase, the Company sold 1,382,488 shares at $2.17 per share for approximately $3,000,000. ($3.0M proceeds)

S-3 filing: This prospectus relates to the resale from time to time of up to 2,008,032 shares of common stock, par value $0.001 per share, of X4 Pharmaceuticals, Inc. by the selling stockholder.

8-K filing: X4 Pharmaceuticals, Inc. entered into a securities purchase agreement with BCLS II Investco, LP, an affiliate of Bain Capital Life Sciences, for a private placement of pre-funded warrants to purchase 2,008,032 shares of common stock at a price of $0.01 per share, with the company expecting to receive gross proceeds of approximately $10.0 million. ($10.0M proceeds)

10-Q filing | 24.7M shares outstanding

10-Q filing | 24.9M shares outstanding

S-3 filing: Resale of 6,321,836 shares of common stock by selling stockholders.

10-Q filing | 23.7M shares outstanding

8-K filing: X4 Pharmaceuticals, Inc. entered into a securities purchase agreement with institutional accredited investors to issue and sell 6,271,836 shares of common stock at $8.70 per share and pre-funded warrants to purchase 50,000 shares of common stock at $0.01 per share, expected to close on March 23, 2021, for gross proceeds of approximately $55.0 million. ($55.0M proceeds)

10-K filing | 17.4M shares outstanding

10-Q filing | 16.3M shares outstanding

S-3 filing: The company is filing an S-3 to register an offering of up to $150,000,000 in common stock, preferred stock, and debt securities from time to time.

S-3 filing: X4 Pharmaceuticals files an S-3 registration statement to offer up to $150,000,000 in various securities, including common stock, preferred stock, and debt securities, as well as up to $50,000,000 of common stock in an at-the-market offering.

10-Q filing | 16.2M shares outstanding

10-Q filing | 16.1M shares outstanding

10-K filing | 0.1M shares outstanding